Minsk Scientific-Practical Center for SurgeryTransplantationHematology
Anti-BCMA CAR-T cells(Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology)은 BCMA 표적 세포·유전자 치료로, Multiple Myeloma Refractory 영역에서 개발·상용화 중입니다. 작용기전: CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 97.1% (ClinicalTrials.gov NCT03548207). 차별점: novel CAR technologies to improve treatment of autoimmune disease.
BCMA
Multiple Myeloma Refractory
Recruiting
CAR-T cells in relapsed or refractory multiple myeloma: a phase 1
lentiviral vector encoding a humanized anti-B cell maturation antigen (BCMA) CAR, in adult
humanized anti-B cell maturation antigen (BCMA) CAR, in adults with relapsed or refractory multiple myeloma
novel CAR technologies to improve treatment of autoimmune disease
CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment
Cytokine release syndrome occurred in four patients (three grade 3 and one grade 2) and was managed with corticoster
BCMA plus dexamethasone had high
bypass ex vivo manufacturing and lymphodepletion, potentially simplifying and accelerating access to cellular therapy; prelimi
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Minsk Scientific-Practical Center for SurgeryTransplantationHematology
Anti-BCMA CAR-T cells(Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology)은 BCMA 표적 세포·유전자 치료로, Multiple Myeloma Refractory 영역에서 개발·상용화 중입니다. 작용기전: CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 97.1% (ClinicalTrials.gov NCT03548207). 차별점: novel CAR technologies to improve treatment of autoimmune disease.
BCMA
Multiple Myeloma Refractory
Recruiting
CAR-T cells in relapsed or refractory multiple myeloma: a phase 1
lentiviral vector encoding a humanized anti-B cell maturation antigen (BCMA) CAR, in adult
humanized anti-B cell maturation antigen (BCMA) CAR, in adults with relapsed or refractory multiple myeloma
novel CAR technologies to improve treatment of autoimmune disease
CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment
Cytokine release syndrome occurred in four patients (three grade 3 and one grade 2) and was managed with corticoster
BCMA plus dexamethasone had high
bypass ex vivo manufacturing and lymphodepletion, potentially simplifying and accelerating access to cellular therapy; prelimi
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.